Get started
Author

Richard K. Brizendine

Observed names: R. Brizendine, Richard Brizendine
ORCID: 0000-0001-9209-2210
Observed ORCID: 0000-0001-9209-2210
OpenAlex ID: A5011578308
Sourcing thermotolerant poly(ethylene terephthalate) hydrolase scaffolds from natural diversity
2022 · Erika Erickson, Japheth E. Gado, et al. · Nature Communications · 192
PDF
Particle Size Reduction of Poly(ethylene terephthalate) Increases the Rate of Enzymatic Depolymerization But Does Not Increase the Overall Conversion Extent
2022 · Richard K. Brizendine, Erika Erickson, et al. · ACS Sustainable Chemistry & Engineering · 117
The role of binding modules in enzymatic poly(ethylene terephthalate) hydrolysis at high-solids loadings
2022 · Rosie Graham, Erika Erickson, et al. · Chem Catalysis · 60
PDF
Velocities of unloaded muscle filaments are not limited by drag forces imposed by myosin cross-bridges
2015 · Richard K. Brizendine, Diego B. Alcala, et al. · Proceedings of the National Academy of Sciences · 42
A mixed-kinetic model describes unloaded velocities of smooth, skeletal, and cardiac muscle myosin filaments in vitro
2017 · Richard K. Brizendine, Gabriel G. Sheehy, et al. · Science Advances · 28
PDF
The Kinetics Underlying the Velocity of Smooth Muscle Myosin Filament Sliding on Actin Filaments in Vitro
2014 · Brian D. Haldeman, Richard K. Brizendine, et al. · Journal of Biological Chemistry · 27
PDF
Diffusion of myosin light chain kinase on actin: A mechanism to enhance myosin phosphorylation rates in smooth muscle
2015 · Feng Hong, Richard K. Brizendine, et al. · The Journal of General Physiology · 22
PDF
Synthesis and Evaluation of 4-Hydroxycoumarin Imines as Inhibitors of Class II Myosins
2020 · Jhonnathan Brawley, Emily Etter, et al. · Journal of Medicinal Chemistry · 16
Myosin light chain kinase steady‐state kinetics: comparison of smooth muscle myosin II and nonmuscle myosin IIB as substrates
2016 · Diego B. Alcala, Brian D. Haldeman, et al. · Cell Biochemistry and Function · 15
Evidence for S2 flexibility by direct visualization of quantum dot–labeled myosin heads and rods within smooth muscle myosin filaments moving on actin in vitro
2020 · Richard K. Brizendine, Murali Anuganti, et al. · The Journal of General Physiology · 6
Using the SpyTag SpyCatcher system to label smooth muscle myosin II filaments with a quantum dot on the regulatory light chain
2019 · Richard K. Brizendine, Murali Anuganti, et al. · Cytoskeleton · 6
A Mixed-Kinetic Model Describes Unloaded Velocities of Smooth, Skeletal, and Cardiac Muscle Myosin Filaments in Vitro
2018 · Richard Brizendine, Gabriel Sheehy, et al. · Biophysical Journal · 3
PDF
Abstract 4729: The reversible and selective FGFR2/3 inhibitor CGT4859 has superior target coverage of resistance mutations missed by leading FGFR inhibitors
2025 · John Fischer, Karyn Bouhana, et al. · Cancer Research · 2
Abstract 5623: Identification of CGT4255 an EGFR sparing, pan-mutant HER2 clinical development candidate with potential best-in-class brain penetration
2025 · Mark J. Chicarelli, Tanna Bettendorf, et al. · Cancer Research · 1
Abstract 3004: Preclinical characterization of CGT6297, a novel PI3Kα H1047R mutant-selective inhibitor
2025 · Aaron C. Smith, Ben Arwood-Levine, et al. · Cancer Research · 1
Both Actin Myosin Attachment and Detachment Kinetics Affect Actin Sliding Velocities and are Influenced by Mechanical Load
2018 · Travis J. Stewart, Sam Dugan, et al. · Biophysical Journal · 1
PDF
Diffusion of myosin light chain kinase on actin: A mechanism to enhance myosin phosphorylation rates in smooth muscle
2015 · Feng Hong, Richard K. Brizendine, et al. · The Journal of Cell Biology · 1
Abstract 410: Characterization of CGT1263, a KRAS (ON/OFF) inhibitor clinical candidate with selectivity for mutant KRAS over HRAS and NRAS.
2026 · John Fischer, Kim Alley, et al. · Cancer Research
Abstract 5869: Preclinical characterization of CGT4255, an EGFR sparing, pan-mutant HER2 clinical development candidate with potential best-in-class brain penetration
2026 · Paul Larsen, Tanna Bettendorf, et al. · Cancer Research
Preclinical characterization of a novel, wild-type-sparing, JAK2 V617F mutant-selective inhibitor
2025 · Mark Chicarelli, Michelle Crow, et al. · Blood
PDF
Abstract B024: Identification of a potent KRAS (ON) inhibitor clinical candidate series with selectivity for mutant KRAS over HRAS and NRAS
2025 · John Fischer, Kim Alley, et al. · Molecular Cancer Therapeutics
Abstract P4-12-19: Preclinical Characterization of a Novel PI3Kα H1047R Mutant-Selective Inhibitor
2025 · Aaron C. Smith, Ben Arwood-Levine, et al. · Clinical Cancer Research
Abstract P4-12-16: Identification of CGT4255 an EGFR sparing, ErbB2 clinical development candidate with activity across activating mutations in systemic and CNS tumors
2025 · Mark J. Chicarelli, Tanna Bettendorf, et al. · Clinical Cancer Research
Abstract 6974: Identification of a potent KRAS (ON) inhibitor with selectivity for mutant KRAS over HRAS and NRAS
2025 · Keith Koch, Kim Alley, et al. · Cancer Research
120 (PB108): Identification of a Potent KRAS Dual On/Off Inhibitor with Selectivity for Mutant KRAS over HRAS and NRAS
2024 · J. Fischer, K. Alley, et al. · European Journal of Cancer
Works count: 37
Citation count: 540
H-index: 9
I10-index: 9
Year
Topic
Type